NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation (Nasdaq:OPHT) today announced that a subgroup analysis assessing the development and progression of sub-retinal fibrosis in the Company’s Phase 2b trial comparing Fovista® (1.5mg) combination therapy with Lucentis® (0.5mg) versus Lucentis® (0.5mg) monotherapy will be presented at the American Academy of Ophthalmology 2014 Annual Meeting in Chicago, Illinois. Sub-retinal fibrosis is a major cause of visual loss in wet age-related macular degeneration (AMD) patients treated with the current standard of care, anti-VEGF monotherapy, according to third party studies1.
Help employers find you! Check out all the jobs and post your resume.
